Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 500 versus HYDROSERPINE PLUS R H H.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 500 versus HYDROSERPINE PLUS R H H.
DIUPRES-500 vs HYDROSERPINE PLUS (R-H-H)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.
None Documented
None Documented
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
Hydroflumethiazide: 2-3 h; reserpine: 50-100 h (biphasic); hydralazine: 2-4 h (fast acetylators), 6-8 h (slow acetylators).
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Hydroflumethiazide: renal (50-65% unchanged); reserpine: renal (30%) and fecal (60%) as metabolites; hydralazine: renal (85% as metabolites, 10% unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination